Recommended hygiene procedures to prevent the spread of SARS-CoV-2 include repeated handwashing and frequent use of hand sanitisers. Both can disrupt skin barrier integrity leading to damaged skin that may contribute to an increased viral transmission. To assess whether damaged skin could represent a potential gateway for SARS-CoV-2, Dr Hanan Osman-Ponchet (PKDERM, Antibes, France) and her team measured the expression levels of SARS-CoV-2 receptors in different human in vitro skin models (i.e. fibroblast and keratinocyte cultures, 3D-skin model, and skin explants), and evaluated the effect of dexamethasone on mRNA expression level of SARS-CoV-2 receptors in these models [1]. “The ultimate goal was to choose the most suitable skin model for the further investigation of a possible skin transmission of SARS-CoV-2,“ Dr Osman-Ponchet explained.
The results showed that angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2) receptors, both important receptors of SARS-CoV-2, are well expressed in skin models, especially in 3D-skin models and skin explants. The level of expression is lower than in a commonly used lung model. Moreover, the expression level of the receptor neuropilin-1 (NRP-1) was similar in skin and lung models. In contrast to lung models, androgen receptor was well expressed in skin models (both in fibroblast cultures and skin explant).
In a second step, the researchers assessed the effect of dexamethasone treatment on the skin models. When keratinocytes were treated with dexamethasone, both IL-8 production in lipopolysaccharides and expression of ACE2 was markedly reduced, an effect that could also be demonstrated in the 3D-skin model. “These results show us that IL-8 and ACE2 expression in skin can be modulated,” Dr Osman-Ponchet said. The fact that SARS-CoV-2 key receptors are expressed in the skin indicates that skin might represent a potential entry route, especially when it is damaged.
- Osman-Ponchet H. Is compromised skin a potential transmission route for SARS-CoV-2? D3T01.2D, EADV Congress 2021, 29 Sept–2 Oct.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Upadacitinib beats dupilumab in different body regions Next Article
AD patients with stable response fare well with a monthly dose of tralokinumab »
« Upadacitinib beats dupilumab in different body regions Next Article
AD patients with stable response fare well with a monthly dose of tralokinumab »
Table of Contents: EADV 2021
Featured articles
Letter from the Editor
Long-term disease control in AD could be in reach with anti-OX40 antibody KHK4083
Late-Breaking News
Targeting OX40 in the treatment of atopic dermatitis meets expectations
Superior EASI scores after switch from dupilumab to upadacitinib
CSU: Novel agent targeting Bruton’s tyrosine kinase leads to disease control
Novel JAK3/TEC blocker leads to maintained re-pigmentation in vitiligo
TYK2 inhibitor deucravacitinib shows impressive long-term response in psoriasis
Tapinarof cream for psoriasis leads to high clearance rates and remittive effect
CSU: Ligelizumab likely safe and effective for adolescents
Long-term disease control in AD could be in reach with anti-OX40 antibody KHK4083
Topical JAK1/JAK2 inhibitor effective in vitiligo
Abrocitinib demonstrates fast itch control and skin clearance in atopic dermatitis
AD patients with stable response fare well with a monthly dose of tralokinumab
Opioid receptor agonist difelikefalin disappoints in AD
Atopic Dermatitis: State of the Art
Upadacitinib beats dupilumab in different body regions
Efficacious 2-year AD control with IL-13 inhibitor tralokinumab
Ruxolitinib cream: a safe treatment for elderly AD patients
Novel and upcoming targeted AD treatment
Psoriasis: What's New?
Existing and upcoming small molecules in psoriasis
Treating psoriasis during pregnancies
A patient-related approach to freedom of disease
Ixekizumab superior to secukinumab in real-world psoriasis study
Nail psoriasis: An important target to be treated
Grand debate: Is psoriasis a systemic or skin-only disease?
Spotlight on Alopecia Areata
JAK1/2: A promising novel treatment target in alopecia areata
Alopecia areata: encouraging response rates with JAK3/TEC inhibition
Related Articles
November 18, 2021
Damaged skin as a possible transmission route for SARS-CoV-2
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com